TATA HEALTH (01255) announces its annual performance in 2023. The company's owners are expected to incur a loss of HKD 322.94 million, a turnaround from profit to loss compared to the previous year.
TATA Health (01255) announced its annual performance for 2023, with revenue of approximately HK$207.5 million, an increase compared to the previous year...
TATA HEALTH (01255) announced its annual performance for 2023, with revenues of approximately HK$207.5 million, an increase of about 43.5% compared to the previous year. The company's attributable loss amounted to HK$32.294 million, a turnaround from profit to loss, resulting in a loss per share of HK$0.13.
The announcement stated that the loss was mainly due to the continued long-term losses and operational stagnation of the healthcare and online medical services business.
Related Articles
Shanghai Bairun Investment Holding Group (002568.SZ) controlling shareholder Liu Xiaodong intends to transfer 63 million shares to Liu Jianguo according to the agreement.
BABA-W (09988) plans to issue approximately 3.2 billion US dollars worth of zero-coupon convertible preferred notes.
Overnight US stocks | The three major indexes are mixed, Oracle Corporation (ORCL.US) rose nearly 36%.
Shanghai Bairun Investment Holding Group (002568.SZ) controlling shareholder Liu Xiaodong intends to transfer 63 million shares to Liu Jianguo according to the agreement.
BABA-W (09988) plans to issue approximately 3.2 billion US dollars worth of zero-coupon convertible preferred notes.
Overnight US stocks | The three major indexes are mixed, Oracle Corporation (ORCL.US) rose nearly 36%.
RECOMMEND
Significant Southbound Capital Inflows into Hong Kong Stocks—Three Investment Directions to Watch
10/09/2025
Heavy-Duty Engine Sales Slide as Weichai Power’s Supplier Payables Near RMB 100 Billion
10/09/2025
U.S. Annual Nonfarm Payroll Revision Misses Expectations with 911,000-Job Cut, Heightening Fed Rate-Cut Pressure
10/09/2025
